Uniqure N.V. (QURE)

$46.06 -0.36 (-0.78%)
Market Cap 3.22B
Revenue (ttm) 16.10M
Net Income (ttm) -198.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,235.84%
Debt to Equity Ratio 0.15
Volume 1,096,800
Avg Vol 2,154,966
Day's Range N/A - N/A
Shares Out 69.37M
Stochastic %K 81%
Beta 0.92
Analysts Strong Sell
Price Target $66.42

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 240 6000
Address:
Paasheuvelweg 25, Amsterdam, Netherlands
MABA1
MABA1 Aug. 10 at 7:11 PM
$QURE on a 40k usd share position at 41usd average. I kinda want to buy more but don’t want to liquidate other positions. But I’m so tempted to pull the trigger
0 · Reply
Coco63
Coco63 Aug. 10 at 3:11 PM
$CAPR It’s the same story with UniQure $QURE . Ten days later, the FDA backtracked under pressure. It’s the same situation here. $30 in a few days.
0 · Reply
Coco63
Coco63 Aug. 10 at 2:04 PM
$CAPR In my opinion, the treatment will be approved by the FDA. For those who followed the uniQure $QURE case: the FDA was initially opposed, yet two weeks later, it approved the treatment.
0 · Reply
MABA1
MABA1 Aug. 10 at 1:49 PM
$REPL Up 7% for the day still. Bro accept your analysis of this company and knowledge in pharma in general is ass and move on. So many stupid takes the last few days. Boxed warning after approval already granted? Accelerated approval is not approval? I was cool with you and your ass takes until you said longs needed to be checked in the head. Anyway, buying more $QURE baby
0 · Reply
alexpitti
alexpitti Aug. 8 at 7:33 PM
my top short ideas are $QURE $PRCT $HROW and $TWST
4 · Reply
MAGA1717
MAGA1717 Aug. 7 at 11:11 PM
$QURE thinkingman is dominating this board like he did the bcrx board. just sayin
0 · Reply
HypnoTrader
HypnoTrader Aug. 7 at 8:33 PM
$QURE fda has a very strict policy prohibiting approval of applications that have not been filed yet.
1 · Reply
ChineseTakeeout
ChineseTakeeout Aug. 7 at 8:32 PM
$QURE Wen approval?
0 · Reply
tttggg
tttggg Aug. 7 at 2:45 PM
$REPL I don’t think the mkt is too impressed by the way FDA calculated the ORR… FDA is sooo arrogant! Even when they did the right thing to approve the drug, they still managed to stab the company in the back one way or another. I hope $QURE will navigate the process better!
1 · Reply
Dexterous9
Dexterous9 Aug. 6 at 11:18 PM
$QURE on my wl for tomorrow
0 · Reply
Latest News on QURE
uniQure price target lowered to $60 from $65 at Barclays

2026-07-30T09:30:50.000Z - 11 days ago

uniQure price target lowered to $60 from $65 at Barclays

Wolfe upgrades uniQure to Outperform, sees ‘clear path to approval’ for AMT-130

2026-07-29T20:16:22.000Z - 12 days ago

Wolfe upgrades uniQure to Outperform, sees ‘clear path to approval’ for AMT-130

uniQure upgraded to Outperform from Peer Perform at Wolfe Research

2026-07-29T20:12:08.000Z - 12 days ago

uniQure upgraded to Outperform from Peer Perform at Wolfe Research

uniQure Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 12 days ago

uniQure Earnings Call Transcript: Q2 2026

uniQure Earnings release: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 12 days ago

uniQure Earnings release: Q2 2026

uniQure Quarterly report: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 12 days ago

uniQure Quarterly report: Q2 2026

uniQure reports Q2 EPS ($1.22), consensus (71c)

2026-07-29T11:30:54.000Z - 12 days ago

uniQure reports Q2 EPS ($1.22), consensus (71c)

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Jul 29, 2026, 7:05 AM EDT - 12 days ago

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure to Announce Second Quarter 2026 Financial Results

Jul 22, 2026, 7:05 AM EDT - 19 days ago

uniQure to Announce Second Quarter 2026 Financial Results

uniQure price target raised to $80 from $50 at H.C. Wainwright

2026-06-29T10:00:16.000Z - 6 weeks ago

uniQure price target raised to $80 from $50 at H.C. Wainwright

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 25, 2026, 4:10 PM EDT - 6 weeks ago

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure price target raised to $68 from $35 at Mizuho

2026-06-25T11:26:12.000Z - 6 weeks ago

uniQure price target raised to $68 from $35 at Mizuho

uniQure 4.95M share Spot Secondary priced at $45.50

2026-06-24T01:51:45.000Z - 6 weeks ago

uniQure 4.95M share Spot Secondary priced at $45.50

uniQure Announces Pricing of Upsized $225 Million Public Offering

Jun 23, 2026, 9:13 PM EDT - 6 weeks ago

uniQure Announces Pricing of Upsized $225 Million Public Offering

UniQure Stock (QURE) Gains on Public Offering Plans

2026-06-23T18:40:00.000Z - 6 weeks ago

UniQure Stock (QURE) Gains on Public Offering Plans

uniQure rises 7.6%

2026-06-23T15:04:50.000Z - 6 weeks ago

uniQure rises 7.6%

uniQure announces $150M offering of common stock

2026-06-22T20:13:29.000Z - 7 weeks ago

uniQure announces $150M offering of common stock

uniQure Announces $150 Million Proposed Public Offering

Jun 22, 2026, 4:01 PM EDT - 7 weeks ago

uniQure Announces $150 Million Proposed Public Offering

uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260

2026-06-19T11:25:07.000Z - 7 weeks ago

uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

Jun 19, 2026, 7:05 AM EDT - 7 weeks ago

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

Barclays upgrades uniQure, calls BLA submission ‘major positive’

2026-06-18T12:22:32.000Z - 7 weeks ago

Barclays upgrades uniQure, calls BLA submission ‘major positive’

uniQure price target raised to $70 from $36 at Leerink

2026-06-18T11:31:03.000Z - 7 weeks ago

uniQure price target raised to $70 from $36 at Leerink

uniQure price target raised to $65 from $35 at RBC Capital

2026-06-18T11:18:09.000Z - 7 weeks ago

uniQure price target raised to $65 from $35 at RBC Capital

uniQure upgraded to Overweight from Equal Weight at Barclays

2026-06-18T11:12:32.000Z - 7 weeks ago

uniQure upgraded to Overweight from Equal Weight at Barclays

uniQure price target raised to $46 from $14 at Goldman Sachs

2026-06-18T10:27:49.000Z - 7 weeks ago

uniQure price target raised to $46 from $14 at Goldman Sachs

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

Jun 17, 2026, 12:12 PM EDT - 7 weeks ago

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

What made uniQure stock nearly double on Wednesday?

Jun 17, 2026, 11:32 AM EDT - 7 weeks ago

What made uniQure stock nearly double on Wednesday?

This Biotech Stock Is Surging 66% on Surprise Good News From FDA

Jun 17, 2026, 10:10 AM EDT - 7 weeks ago

This Biotech Stock Is Surging 66% on Surprise Good News From FDA

UniQure gets FDA green light to file for Huntington's gene therapy approval

Jun 17, 2026, 7:13 AM EDT - 7 weeks ago

UniQure gets FDA green light to file for Huntington's gene therapy approval

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease

Jun 17, 2026, 7:05 AM EDT - 7 weeks ago

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease

uniQure Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

uniQure Earnings Call Transcript: Q1 2026

uniQure Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

uniQure Earnings release: Q1 2026

uniQure Quarterly report: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

uniQure Quarterly report: Q1 2026

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

May 5, 2026, 7:05 AM EDT - 3 months ago

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

Apr 30, 2026, 7:05 AM EDT - 3 months ago

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

uniQure to Announce First Quarter 2026 Financial Results

Apr 28, 2026, 7:05 AM EDT - 3 months ago

uniQure to Announce First Quarter 2026 Financial Results

uniQure Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

uniQure Proxy statement: Proxy filing

uniQure Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

uniQure Proxy statement: Proxy filing

uniQure Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

uniQure Proxy statement: Proxy filing

This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down

Mar 9, 2026, 9:18 AM EDT - 5 months ago

This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down

Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying

Mar 5, 2026, 6:01 PM EST - 5 months ago

Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying

FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease

Mar 5, 2026, 2:42 PM EST - 5 months ago

FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease

Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

Mar 5, 2026, 1:11 PM EST - 5 months ago

Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

FDA official says UniQure fell short on Huntington's trial, defends new study request

Mar 4, 2026, 11:01 PM EST - 5 months ago

FDA official says UniQure fell short on Huntington's trial, defends new study request

uniQure Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 5 months ago

uniQure Transcript: TD Cowen 46th Annual Health Care Conference

uniQure Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:00 AM EST - 5 months ago

uniQure Earnings Call Transcript: Q4 2025

uniQure Earnings release: Q4 2025

Mar 2, 2026, 8:00 AM EST - 5 months ago

uniQure Earnings release: Q4 2025

uniQure Annual report: Q4 2025

Mar 2, 2026, 8:00 AM EST - 5 months ago

uniQure Annual report: Q4 2025

FDA tells UniQure study data insufficient for brain disorder therapy application

Mar 2, 2026, 7:22 AM EST - 5 months ago

FDA tells UniQure study data insufficient for brain disorder therapy application

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

Mar 2, 2026, 7:05 AM EST - 5 months ago

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

Feb 25, 2026, 6:00 PM EST - 5 months ago

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

uniQure to Announce 2025 Financial Results

Feb 23, 2026, 7:05 AM EST - 6 months ago

uniQure to Announce 2025 Financial Results

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 18, 2026, 10:06 AM EST - 6 months ago

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

Feb 17, 2026, 8:16 AM EST - 6 months ago

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Feb 6, 2026, 7:05 AM EST - 6 months ago

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

uniQure Slides: Corporate presentation

Jan 13, 2026, 7:00 AM EST - 7 months ago

uniQure Slides: Corporate presentation

uniQure Announces Type A Meeting Scheduled with FDA

Jan 9, 2026, 7:05 AM EST - 7 months ago

uniQure Announces Type A Meeting Scheduled with FDA

MABA1
MABA1 Aug. 10 at 7:11 PM
$QURE on a 40k usd share position at 41usd average. I kinda want to buy more but don’t want to liquidate other positions. But I’m so tempted to pull the trigger
0 · Reply
Coco63
Coco63 Aug. 10 at 3:11 PM
$CAPR It’s the same story with UniQure $QURE . Ten days later, the FDA backtracked under pressure. It’s the same situation here. $30 in a few days.
0 · Reply
Coco63
Coco63 Aug. 10 at 2:04 PM
$CAPR In my opinion, the treatment will be approved by the FDA. For those who followed the uniQure $QURE case: the FDA was initially opposed, yet two weeks later, it approved the treatment.
0 · Reply
MABA1
MABA1 Aug. 10 at 1:49 PM
$REPL Up 7% for the day still. Bro accept your analysis of this company and knowledge in pharma in general is ass and move on. So many stupid takes the last few days. Boxed warning after approval already granted? Accelerated approval is not approval? I was cool with you and your ass takes until you said longs needed to be checked in the head. Anyway, buying more $QURE baby
0 · Reply
alexpitti
alexpitti Aug. 8 at 7:33 PM
my top short ideas are $QURE $PRCT $HROW and $TWST
4 · Reply
MAGA1717
MAGA1717 Aug. 7 at 11:11 PM
$QURE thinkingman is dominating this board like he did the bcrx board. just sayin
0 · Reply
HypnoTrader
HypnoTrader Aug. 7 at 8:33 PM
$QURE fda has a very strict policy prohibiting approval of applications that have not been filed yet.
1 · Reply
ChineseTakeeout
ChineseTakeeout Aug. 7 at 8:32 PM
$QURE Wen approval?
0 · Reply
tttggg
tttggg Aug. 7 at 2:45 PM
$REPL I don’t think the mkt is too impressed by the way FDA calculated the ORR… FDA is sooo arrogant! Even when they did the right thing to approve the drug, they still managed to stab the company in the back one way or another. I hope $QURE will navigate the process better!
1 · Reply
Dexterous9
Dexterous9 Aug. 6 at 11:18 PM
$QURE on my wl for tomorrow
0 · Reply
RichSaunder
RichSaunder Aug. 6 at 8:34 PM
$REPL approved Tic Toc $CLPT $QURE
0 · Reply
KirRoyalTrader
KirRoyalTrader Aug. 6 at 5:32 PM
$QURE uniQure is pressing for a breakout from a very tight consolidation above the PEG AVWAP. The setup looks clean and constructive. 👀
0 · Reply
ExploringTrades
ExploringTrades Aug. 5 at 11:24 AM
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $QURE %N
0 · Reply
alexpitti
alexpitti Aug. 4 at 1:43 PM
$CLPT is expensive, doesn't grow quickly, burns a ton of cash, needs to raise cash, relies on $QURE which won't get approved. i think clpt is headed to $8
2 · Reply
Roronao
Roronao Aug. 4 at 9:42 AM
$NEON $LAC $QURE on30
0 · Reply
Merlintrader
Merlintrader Aug. 4 at 9:31 AM
uniQure (Nasdaq: $QURE) Stock Hub: AMT-130, the FDA Reversal and the Q3 2026 BLA Path https://www.merlintrader.com/uniqure-stock-hub/
0 · Reply
Roronao
Roronao Aug. 3 at 11:55 PM
$QURE $HSAI Chess-
0 · Reply
JFais
JFais Aug. 3 at 10:01 PM
$CLPT to DD list on Q2 "sell the news" reaction Partners $QURE et al on track, market focused on short-term setbacks but missing forest for the trees IMO
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 3 at 12:00 AM
$QURE $CAPR
1 · Reply
tomorrowverse
tomorrowverse Aug. 2 at 9:37 PM
$QURE This is my 3rd position on QURE for the last 3 years and I have generated more than 1000% cumulative returns. My current 3rd position has 94.68% profit and I will not take profit. For those of you worried about Ad Com, you obviously didn't do much research on Huntington Disease and enrollment criteria. I will say don't worry and offer my 3 insights. HD deteriorates rapidly at 3rd year and QURE already has secured robust functional data. Biomarker data is secondary to functional data and still robust. I have listened to the entire Ad Com for both CAPR (6H) and REPL (7H) last week. Compared to clinical data shortcomings the FDA validly raised on these two companies, HD data is solid. Some weak hands or novice specialists may point to limited dataset and natural history data instead of placebo. My simple answer is do not worry. Ad Com will work in favor of, rather than against, QURE. HD is rare disease and current LT data is more than sufficient to get FDA approval.
2 · Reply
Monkey7779192
Monkey7779192 Aug. 1 at 12:18 AM
$QURE Potentially getting an adcom. Lets see how to play this. Its tough to guess whats the result going to be.
1 · Reply
MABA1
MABA1 Jul. 31 at 2:15 PM
$REPL for anyone following my trades, I sold into close to the peak for a very healthy gain, one of those of its good to screenshot its good to sell. I’m keeping a very small portion of shares just for the heck of it, hedged just for the heck of it x2. CRL is still a possibility, I don’t like to talk in 100% certainties unlike some of the ass bears in this thread. If it gets approved i get some extra dough , nothing crazy. If refused it’s chill, already made plenty. Next moves? I parked some of the profits on my core safe holdings , in this case Apple. Also I doubled my position on $QURE . Other pharma companies? I need to go back to the cave for the deep dives. Im really tempted to buy more sarepta , but I need to refresh my memory on the arrowhead compounds and where those are at. Maybe a IOVA put? I don’t like to buy puts on pharma companies with actual products so I’ll probably skip that one.
1 · Reply